Chun Chen's questions to Bristol-Myers Squibb Co (BMY) leadership • Q3 2024
Question
Chun Chen inquired about the recent PRMT5 inhibitor data, asking about the durability of response and which tumor types the company plans to prioritize for further development.
Answer
Head of Global Drug Development Samit Hirawat described the data as very encouraging, highlighting non-small cell lung cancer (NSCLC) with a ~31% overall response rate and a 10.5-month duration of response. He also noted promising activity in pancreatic cancer and stated that an update on later-phase development plans would be provided next year.